

MedMira Inc.

Management's Discussion & Analysis

For the six months ended January 31, 2022

Forward looking statements

This document contains forward looking statements, such as statements regarding future sales opportunities in various global regions and financing initiatives that are based on current expectations of management. These statements involve uncertainties and risks, including MedMira Inc.'s ("MedMira" or the "Company") ability to obtain and/or access additional financing with acceptable terms, and delays in anticipated product sales. Such forward-looking statements should be given careful consideration and undue reliance should not be placed on these statements.

This MD&A contains statements that may constitute forward-looking statements about the Company's objectives, strategies, financial condition, results of operations, cash flows and businesses. These statements are "forward-looking" because they are based on current expectations, estimates, assumptions, risks and uncertainties. These forward-looking statements are typically identified by future or conditional verbs such as "outlook", "believe", "anticipate", "estimate", "project", "expect", "intend", "plan", and terms and expressions of similar import. Such forward-looking statements are subject to a number of risks and uncertainties that include, but are not limited to: cyclical downturn; competitive pressures; dealing with business and political systems in a variety of jurisdictions; repatriation of funds or property in other jurisdictions; payment of taxes in various jurisdictions; exposure to currency movements; inadequate or failed internal processes, people or systems or from external events; dependence on key customers; safety performance; expansion and acquisition strategy; regulatory and legal risk; corruption, bribery or fraud by employees or agents; extreme weather conditions and the impact of natural or other disasters; shortage of specialized skills and cost of labour increases; equipment and parts availability, reputational risk; cybersecurity risk; market price and dilution of common shares and environmental regulation risk. Actual results could be materially different from expectations if known or unknown risks affect the business, or if estimates or assumptions turn out to be inaccurate. The Company does not guarantee that any forward-looking statement will materialize and, accordingly, the reader is cautioned not to place reliance on these forward-looking statements. The Company disclaims any intention and assumes no obligation to update any forward-looking statement, even if new information becomes available, as a result of future events or for any other reasons, except in accordance with applicable securities laws.

Introduction

The MD&A was issued and approved by the Board of Directors on the 31st day of March 2022. The following MD&A for the six months ended January 31, 2022 has been prepared to help investors understand the financial performance of MedMira in the broader context of the Company's strategic direction, the risk and opportunities as understood by management, and the key metrics that are relevant to the Company's performance. The Audit Committee of the Board of Directors has reviewed this document and all other publicly reported financial information for integrity, usefulness, reliability and consistency.

This document should be read in conjunction with the audited consolidated financial statements for the year ended July 31, 2021. Annual references are to the Company's fiscal years, which end on July 31. All amounts are expressed in Canadian dollars ("CAD") unless otherwise noted.

Additional information about MedMira, this document, and the related quarterly financial statements ended January 31, 2022 can be viewed on the Company's website at www.medmira.com and are available on SEDAR at www.sedar.com.

The preparation of Management's Discussion and Analysis ("MD&A") may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Management bases estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results may differ

from these estimates under different assumptions or conditions. Management believes the accounting policies, outlined in the Significant Accounting Policies section of its January 31, 2022 consolidated financial statements, affect its more significant judgments and estimates used in the preparation of its consolidated financial statements.

About MedMira

MedMira is a biotechnology company engaged in the development and commercialization of rapid diagnostics and technology platforms. The Company is headquartered in Halifax, Nova Scotia, Canada and is listed on the TSX Venture Exchange ("TSX-V") under the symbol MIR.

The patented MedMira Rapid Vertical Flow (RVF) Technology® platform is the basis for the Company's line of rapid tests. Diagnostic applications based on this technology are highly accurate, easy-to-use, and produce instant results – a strong advantage over most other rapid diagnostics on the market today. These features are enhanced further with ability to deliver multiplex results on one test device with just one drop of specimen. The Company has created a new generation of rapid tests that are based on the need to provide immediate answers without increasing costs.

MedMira's technology platform and growing portfolio of diagnostic tools demonstrate excellence in performance and quality in the highly competitive diagnostics industry. More than \$30 million has been invested in perfecting MedMira's core technology, which has proven itself time and time again with its excellent clinical performance and its success in rigorous evaluations and inspections, leading to regulatory approvals for rapid diagnostic solutions in the United States (US Food and Drug Administration), Canada (Health Canada), the notified body in the European Union (CE Mark), and China (CFDA) and in a number of countries in Latin America, Africa, and Asia. The Company's quality system is ISO 9001 and ISO 13485 certified.

MedMira sells its rapid tests through a network of medical distributors and strategic business development partners to customers in all sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies.

In addition to clinical diagnostics, the Company offers the Miriad™ product line to create new opportunities in the high value technology licensing sector. This business line allows the Company to monetize its award-winning technology and core capabilities, including R&D, product development, and regulatory proficiency. Miriad provides access to MedMira's RVF Technology for researchers, developers, and biotech companies on a license basis to facilitate the creation of new rapid tests or the transition of existing tests to this unique platform. Infiltrating new and different sectors of the diagnostic industry, such as veterinary and environmental, with the Company's technology, enables MedMira to build a higher degree of global awareness, generate new revenue streams, and provide a superior diagnostic platform to the market.

Intellectual property

The Company strives to protect its intellectual property in established and emerging markets around the world as warranted. MedMira's intellectual property portfolio for its Rapid Vertical Flow Technology and the methodology behind its rapid diagnostics includes the following:

<i>Patent #</i>	<i>Title</i>	<i>Jurisdiction</i>
9,164,087	Rapid Diagnostic Device, assay and multifunctional Buffer	United States
9,086,410	Downward or vertical flow diagnostic device and assay	United States
8,025,850	Rapid Diagnostic Device, Assay and Multifunctional Buffer	United States

8,287,817	Rapid Diagnostic Device, Assay and Multifunctional Buffer	United States
8,586,375	Rapid Diagnostic Device, Assay and Multifunctional Buffer	United States
7,531,362	Rapid Diagnostic Device, Assay and Multifunctional Buffer	United States
D706945	Diagnostic Device	United States
D706466	Diagnostic Device	United States
EP1417489	Rapid Diagnostic Device and Assay	Europe
ZL02819646.5	Rapid Diagnostic Device and Assay	China
2,493,616	Rapid Diagnostic Device, Assay and Multifunctional Buffer	Canada

The Company has other patents pending patents in the US as well as two design patents in force or pending in eight markets. The Company's corporate and product brand names are protected by trademarks in the US and Canada.

The Company has recorded an impairment charge in previous fiscal years to write-down its intangible assets to a nominal value. There is no indication at the end of January 31, 2022 that this impairment has been reversed and thus the value of intangible assets on the balance sheet on January 31, 2022 is \$2 (July 31, 2021 - \$2).

Corporate update

In the second financial quarter of FY2022, MedMira continued its strategic plan to focus its own product portfolio on the two fastest growing disease segments in the IVD rapid test market. Furthermore, the Company continued its work with public and private partners to develop new potential tests based on its Rapid Vertical Flow (RVF) Technology® platform.

Sexually Transmitted Infections (STI)

MedMira has positioned itself with its HIV, HCV (Hepatitis C), TP (Syphilis) products in these three major and fastest growing STI segments. The growth rate for each of the markets are at a CAGR between 3 – 6 %, which highlights the significant potential for MedMira's high quality rapid testing solutions. In addition, recent steps taken by regulators to prioritise testing alternatives such as rapid testing for these diseases further outline the high demand MedMira's products.

COVID-19

Currently there is a growing trend to shift SARS-CoV-2 from a pandemic to an endemic situation. Whereas this change may be more politically and economically motivated, it contrasts with the scientific data which show an increasing prevalence rate. The need for testing may not be a requirement or an obligation by public institutions, however, it will steadily move towards home testing and self-protection. Decreasing or ending public requirements to protect individuals from SARS-CoV-2 may result in further large-scale outbreaks over time.

In a press release issued by the US National Institute of Health (NIH) on March 31, 2022 stated "Dr. Fauci and his colleagues write that achieving classical herd immunity against SARS-CoV-2 is unlikely, due to a combination of factors that include features of the virus as well as current societal dynamics. These include the virus' ability to continually mutate to new variants; asymptomatic virus transmission, which complicates public health control strategies; the inability of prior infection or vaccination to provide durable protection against reinfection; suboptimal vaccination coverage; and adherence to non-pharmacologic interventions." Living with COVID is best considered not as reaching a numerical threshold of immunity, but as optimizing population protection without prohibitive restrictions on our daily lives, the authors conclude.

Notwithstanding the terminology or public perception of the severeness of SARS-CoV-2 moving forward, testing is and continuous to be essential for health care providers and individuals. MedMira's four COVID-19 products provide a testing

solution to screen (antigen testing) for acute infections, monitor protection levels (antibody testing) and provide an answer for end-users Covid-19 or Flu. Screen, monitor – know.

Regulatory update United States

In January 2022, the U.S. FDA announced the introduction of the traditional approval under the classification of the De Novo/510(k) Classification Request process. This is a pathway for manufacturers of novel medical devices seeking marketing authorization as a Class I or Class II device. The advantages of the De Novo Classification Request for new devices include expeditious review times and a fixed classification decision lending to more certainty within the device's regulatory lifespan. While the EUA process is on-going, the Company has prepared the necessary De Novo 510(k) pre-submissions for its REVEALCOVID-19® and VYRA™ product lines. Due to further considerations, the process has not yet been fully implemented for rapid testing system and the Company is awaiting the final guideline in order to commence with its application. The first and only De Novo 510(k) clearance of molecular SARS-CoV-2 test was given to the BioFire Respiratory Panel 2.1 on March 17, 2021. FDA has not yet cleared any subsequent 510 (k) for molecular SARS-CoV-2 diagnostic test since. While the De Novo 510(k) regulatory process for rapid test is still pending, the Company has had communications with FDA on the current pre-submissions for SARS-CoV-2 related product lines.

During the second financial quarter of 2022, the Company filed its pre-submission for the De Novo/510(k) Classification Request for its Reveal® Hepatitis C (HCV) Rapid Antibody Test and received the letter of acknowledgment from FDA (CDRH). Our clinical development team has been working closely with the clinical research organization (CRO) in clinical site selection in US while FDA is reviewing the submitted clinical trial protocol. We anticipate the clinical trial may take place in early summer this year.

MedMira's Reveal® G4 HIV test, was previously FDA/PMA approved, has started the clinical trials required to complete its last phase of regulatory work to obtain the FDA CLIA-waived listing. This new claim allows the Company to access the over USD\$ 350 million annual market in the United States which includes physician-office-lab (POL) facilities, clinics, and other community healthcare providers.

Regulatory Update Europe

Subsequent to the end of the second financial quarter of FY2022, the Company received the CE mark for its REVEALCOVID-19® PLUS Total Antibody Test and commenced its commercialization efforts in all markets accepting the CE mark. Sales generated from this product will contribute towards the Company's overall sales within the coming months. Furthermore, the Company is anticipating at least two additional CE marks for its other COVID-19 products within the coming two months. In addition, MedMira will commence on at least one CE mark application for a Sexually Transmitted Disease test (to be announced at a later stage) prior to the 26th of May 2022.

Changes to the regulatory framework in the CE marketplace

The European Medical Device landscape is in the process of dramatic change, attributable to the upcoming introduction of Regulation (EU) 2017/746, better known as the IVDR (In-Vitro Diagnostic Regulation). The IVDR will replace the existing medical device regulation, IVDD, and will cover all EU member states.

The additional considerations introduced by the IVDR apply to all manufacturers seeking CE marking for new medical devices and existing devices previously certified under the IVDD (i.e., legacy devices). These considerations include more rigorous risk classifications, quality management system requirements, and performance evaluation standards. Approvals under the IVDR will require more time and effort from both manufacturers and Notified Bodies, who are now responsible for certifying 80% of prospective medical devices (compared to 20% under the IVDD).

Legacy devices will be subject to gap analysis after May 26, 2022, when they must meet the strict requirements of the IVDR on-top of their existing conformity to the IVDD. Many self-certified devices, however, will need to undergo a complete IVDR

conformity assessment and certification through a Notified Body. The deadline for this approval depends on the new IVDR risk classification of formerly self-certified devices and will require a major commitment from manufacturers.

As a result, higher entry barriers will be established in the CE market place and a more stringent focus will be placed on the quality of components, manufacturing processes and standards, and performance quality of products. With this change, CE approval will be aligned closer to the strict regulatory framework as applied by the U.S. FDA. This provides a unique opportunity for manufacturers such as MedMira which have built over the years high quality manufacturing processes and achieved the necessary accreditations. The Company's focus on the quality of its products and acquisition of supporting evidence will be key to its future success in the CE market place. It is management's view that these changes will significantly impact the competitive landscape and the pricing model in favour of MedMira.

Regulatory Update Canada

A partnership with REACH Nexus (www.reachnexus.ca) at the MAP Centre for Urban Health Solutions (www.maphealth.ca) was entered into for the sponsorship of the clinical trials in Canada was agreed. The partnership will allow the Company to perform a clinical trial evaluation at 10 testing sites and with the data generated, a Health Canada approval can be achieved. At this stage, MedMira's Reveal® TP (Syphilis) Rapid Test would be only product available on the Canadian market. Subsequent to the end of the second financial quarter FY2022, MedMira filled its ITA which is currently under review by Health Canada. After the approval, the Company is able to commence with the clinical trials.

COVID-19: The third (3) Interim Order process has been released by Health Canada as of February 21, 2022 relating to COVID-19 products which has allowed MedMira to discuss pending and future applications. *"Whereas the Minister of Health believes that immediate action is required to deal with a significant risk, direct or indirect, to health, safety or the environment. Therefore, the Minister of Health, pursuant to subsection 30.1(1) of the Food and Drugs Act, makes the annexed Interim Order No. 3 Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19."* Ottawa, February 21, 2022, Jean-Yves Duclos, Minister of Health.

As a result of these discussions the Company was informed that the priority is set at SARS-CoV-2 antigen home tests and a more efficient process has been established to decrease the review time; increase communication; and allow Canadian manufacturers to support the government's increasing demand for SARS-CoV-2 antigen tests. While antibody testing is not yet a priority, the Company REVEALCOVID-19® Total Antibody Test application is still pending. Currently the focus is set on antigen testing in anticipation of the next wave that may cause higher infections within Canada. The Company welcomes these regulatory new processes and can move forward with its application for VYRA™ Antigen Tests. Data received from independent evaluations carried out in recent month in both Canada and Germany demonstrated accuracy close to 100% in identify acute SARS-CoV-2 infected patients.

Sales update

In Q2 FY2022, the Company recorded higher sales of its non-COVID-19 products in comparison to the last financial quarter which was in line with management's expectations. Sales for its COVID-19 products were significant lower in comparison to the same financial quarter last year which was mainly due to the temporary halt in sales in the US for its REVEALCOVID-19® Antibody Test until the EUA has been granted. Subsequent to Q2 FY2022 and the CE mark of REVEALCOVID-19® PLUS Antibody Test, MedMira will generated higher sales for this product line. Furthermore, the CE mark of MedMira's Reveal® TP (Syphilis) Rapid Test received in March 2022, will further enhance its overall sales in the coming financial quarters. The increasing prevalence rates of Syphilis globally and the support of various governments in Europe to offer free or subsidised testing provides a substantial sales opportunity for MedMira's easy-to-use and highly sensitive Syphilis test.

Financial update

The Company's Finance team continued its fiscal constraints to maintain its low fixed costs with the aim to achieve breakeven and subsequent profitability within a short period of time. During FY2022, the Company continued its efforts to

renegotiate its debt and achieved a forbearance agreement with MedMira's largest debt holder which allows the Company to defer principal and interest payments for 12 months. This may be extended further depending on the growth of the Company. In Q2 FY2022, MedMira completed a financial package agreement with its largest shareholders. This provided the Company with additional cash to execute its clinical trials (G4 HIV CLIA-waived Rapid Test), to continue its operations and to further invest into the manufacturing facility in Halifax. Furthermore, MedMira's largest shareholders have converted \$3,564,435.92 debt into shares in order to support the Company in its efforts to reduce its debts and support its going concern.

Financial results

Basis of preparation and significant accounting policies

The basis of financial statement preparation and the significant accounting policies of MedMira are described in Notes 2 and 3 of the Company's condensed interim consolidated financial statements for the six months ended January 31, 2022.

Selected quarterly information (in thousands of dollars except per share amounts)

Income statement	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020
	\$	\$	\$	\$	\$	\$	\$	\$
Revenue	298	202	110	84	347	1,603	648	87
Cost of sales	(212)	(177)	(25)	(48)	(109)	(241)	(297)	(17)
Gross profit	86	25	85	36	238	1,362	351	70
Operating expenses	(445)	(414)	(697)	(233)	(497)	(479)	(403)	(603)
Other expenses (gains)	(109)	(25)	(141)	(158)	(168)	(218)	(160)	(182)
Net earnings (loss) before tax	(468)	(414)	(753)	(355)	(427)	665	(212)	(715)

Balance sheet	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020
	\$	\$	\$	\$	\$	\$	\$	\$
Current assets	2,340	2,603	1,576	1,342	1,610	2,123	911	656
Non-current assets	2,214	2,265	2,314	2,337	2,389	2,437	2,485	2,442
Total assets	4,554	4,868	3,890	3,679	3,999	4,560	3,396	3,098
Current liabilities	13,905	18,911	17,414	17,026	16,763	16,300	15,806	16,009
Non-current liabilities	2,131	2,172	2,200	2,239	2,484	3,107	3,152	2,381
Total liabilities	16,036	21,083	19,614	19,265	19,247	19,407	18,958	18,390
Total shareholders deficiency	(11,482)	(16,215)	(15,724)	(15,586)	(15,248)	(14,847)	(15,562)	(15,292)
Total liabilities and equity	4,554	4,868	3,890	3,679	3,999	4,560	3,396	3,098

This quarterly information is unaudited but has been prepared on the same basis as any other annual consolidated financial statements. We discuss the factors that caused our results to vary over the past eight quarters throughout this MD&A. The main highlights are:

- The decrease in revenue for fiscal 2022 compared to fiscal 2021 is directly related to the temporary halt imposed by the US FDA on sales of non-Emergency Used Authorized (EUA) products in January 2021. This affected temporarily the sales of the Company's REVEALCOVID-19® Total Antibody Test in the United States in the subsequent quarters. The Company expects these revenues to increase over the next financial quarters with the receipt of the regulatory authorization in the United States and in Europe.

- The decrease in operating expenses is a direct result of the Company's decrease in other direct costs associated with sales and R&D contributions towards research and development expenses.
- The decrease in other expenses over the last several quarters is in direct relation to the decreased amount of accounts payable that the Company is carrying specifically its debt to MedMira's largest shareholders.

Second quarter analysis

	For the three months ended		
	31-Jan-22	31-Jan-21	Better(worse)
	\$	\$	\$
Product			
Product sales	102,615	323,642	(221,027)
Product cost of sales	(17,025)	(85,505)	68,480
Gross margin on product	<u>85,590</u>	<u>238,137</u>	<u>(152,547)</u>
Services			
Service sales	194,870	23,801	171,069
Service cost of sales	(194,870)	(23,801)	(171,069)
Gross margin on services	<u>-</u>	<u>-</u>	<u>-</u>
Operating expenses			
Research and development	13,289	(72,523)	85,812
Sales and marketing	326	(25,213)	25,539
Other direct costs	(225,799)	(289,289)	63,490
General and administrative	(233,017)	(109,510)	(123,507)
Total operating expenses	<u>(445,201)</u>	<u>(496,535)</u>	<u>51,334</u>
Operating loss	<u>(359,611)</u>	<u>(258,398)</u>	<u>(101,213)</u>
Non-operating income (expenses)			
Government Assistance	-	-	
Financing	(108,730)	(157,534)	48,804
Net (loss) income	<u>(468,341)</u>	<u>(415,932)</u>	<u>(52,409)</u>

Product revenue and gross margin

The Company recorded revenue from product sales in the three months ended January 31, 2022 of \$105,615 as compared to \$325,642 for the same period last year. The Company's decreased revenue is directly related to the temporary halt imposed by the US FDA on sales of non-Emergency Used Authorized (EUA) products in January 2021. This affected temporarily the sales of the Company's REVEALCOVID-19® Total Antibody Test in the United States in the subsequent quarters. The Company expects these revenues to increase over the next financial quarters with the receipt of the regulatory authorization in the United States and in Europe.

Gross profit on product sales for the three months ended January 31, 2022 of \$85,590 compared to \$238,137 for the same period in fiscal 2021. The Company's gross profit decrease is directly related to the lower recorded sales.

Service revenue and gross margin

The Company recorded revenue from service sales in the three months ended January 31, 2022 of \$194,870 compared to

\$23,801 for the same period in fiscal 2021. The increase in service revenue is directly related to the continuation of the Company's regulatory work for its REVEALCOVID-19® and VYRA™ product line. There was no gross profit margins generated from service sales as expected by the management.

Operating expenses

Total operating expenses decreased by \$51,334 from \$496,535 for the three months ended January 31, 2021 to \$445,201 for the three months ended January 31, 2022.

- Research and development expenses for the three months ended January 31, 2022 were a recovery of \$13,289 compared to a \$72,523 for the same period in fiscal 2021. The decrease and recovery was due to the completion of the development of the product VYRA™ CoV2Flu and the Company's additional new products to be announced at a later stage after validations has been completed.
- Sales and marketing expenses for the three months ended January 31, 2022 were a recovery \$326 compared to \$25,213 for the same period in fiscal 2021. The decrease of approximately 97% was related to the temporary halt imposed by the US FDA on sales of non-Emergency Used Authorized (EUA) products in January 2021. This affected temporarily the sales of the Company's REVEALCOVID-19® Total Antibody Test in the United States in the subsequent quarters. The Company expects these costs to increase over the next financial quarters with the receipt of the regulatory authorization in the United States and in Europe.
- Other direct costs for the three months ended January 31, 2022 were \$225,799, compared to \$289,289 for the same period in fiscal 2021. Other direct costs decreased by approximately 22% is directly related to the lower recorded sales.
- General and administrative expenses were \$233,017 for the three months ended January 31, 2022 compared to \$109,510 for the same period in fiscal 2021. The increase of approximately 53% was mainly due to the Company's increase in its regulatory work and clinical trial costs associated with COVID-19 and other new products pending further evaluations and approvals.

Non-operating expenses

- Total financing expenses were \$108,730 in the three months ended January 31, 2022 compared to \$157,534 during the same period in fiscal year 2021. The decrease of 31% in financing expenses was mainly due to the significant loan conversion by the Company's largest shareholder.

Year to date Analysis

	For the six months ended		
	31-Jan-22	31-Jan-21	Better(worse)
	\$	\$	\$
Product			
Product sales	143,346	1,889,386	(1,746,040)
Product cost of sales	(33,063)	(288,978)	255,915
Gross margin on product	110,283	1,600,408	(1,490,125)
Services			
Service sales	356,300	60,880	295,420
Service cost of sales	(356,300)	(60,880)	(295,420)
Gross margin on services	-	-	-
Operating expenses			
Research and development	(34,316)	(134,295)	99,979
Sales and marketing	(230)	(42,512)	42,282
Other direct costs	(444,676)	(521,051)	76,375
General and administrative	(379,706)	(277,598)	(102,108)
Total operating expenses	(858,928)	(975,456)	116,528
Operating loss	(748,645)	624,952	(1,373,597)
Non-operating income (expenses)			
Government Assistance	64,703	-	64,703
Financing	(273,408)	(325,712)	52,304
Net (loss) income	(957,350)	299,240	(1,256,590)

Product revenue and gross margin

The Company recorded revenue from product sales in the six months ended January 31, 2022 of \$143,346 as compared to \$1,889,386 for the same period last year. Gross profit on product sales for the six months ended January 31, 2022 was \$110,283 compared to \$1,600,408 for the same period in 2021. The Company's decreased revenue is directly related to the temporary halt imposed by the US FDA on sales of non-Emergency Used Authorized (EUA) products in January 2021. This affected temporarily the sales of the Company's REVEALCOVID-19® Total Antibody Test in the United States in the subsequent quarters. The Company expects these revenues to increase over the next financial quarters with the receipt of the regulatory authorization in the United States and in Europe

Service revenue and gross margin

The Company recorded revenue from service sales in the six months ended January 31, 2022 of \$356,300 compared to \$60,880 the same period in 2021.

Operating expenses

Total operating expenses decreased by \$116,528 from \$975,456 for the six months ended January 31, 2022 to \$858,928 for the six months ended January 31, 2021.

- Research and development expenses for the six months ended January 31, 2022 were \$34,316 compared to \$134,295 for the same period in 2021. The decrease of approximately 74% was due to the completion of the development of the product VYRA™ CoV2Flu and the Company's additional new products to be announced at a later stage after

validations has been completed.

- Sales and marketing expenses for the six months ended January 31, 2022 were \$230 compared to \$42,512 for the same period in 2021. The decrease was related to the temporary halt imposed by the US FDA on sales of non-Emergency Used Authorized (EUA) products in January 2021. This affected temporarily the sales of the Company's REVEALCOVID-19® Total Antibody Test in the United States in the subsequent quarters. The Company expects these costs to increase over the next financial quarters with the receipt of the regulatory authorization in the United States and in Europe.
- Other direct costs for the six months ended January 31, 2022 were \$444,676, compared to \$521,051 for the same period in 2021. This decrease of approximately 15% was due to the lower recorded sales.
- General and administrative expenses were \$379,706 for the six months ended January 31, 2022, compared to \$277,598 for the same period in 2021. This 113% increase was mainly due to the Company's regulatory work and clinical trial costs associated with COVID-19 and other new products pending further evaluations and approvals.

Non-operating expenses

- Total non-operating expenses were \$208,705 in the six months ended January 31, 2022, compared to \$325,712 during the same period in 2021. The decrease of 31% in financing expenses was mainly due to the significant loan conversion by the Company's largest shareholder.

Geographic information

The Company organizes and records the sales and distribution of its products based on major geographical territories around the world. The table below provides the three-month geographic breakdown of revenue.

	for the three months ended		for the six months ended	
	31-Jan-22	31-Jan-21	31-Jan-22	31-Jan-21
			\$	\$
North America	292,584	105,960	492,873	1,702,975
Asia Pacific	-	4,083	454	8,039
Europe	4,901	235,486	6,319	237,338
Other	-	1,914	-	1,914
Total revenue	297,485	347,443	499,646	1,950,266

Liquidity and capital resources

Cash and working capital

The Company had a cash reserves of \$937,256 on January 31, 2022 as cash of nil on July 31, 2021. The Company's net working capital position as at January 31, 2022 was a deficit of \$11.6 million compared to the July 31, 2021 working capital deficit of \$15.8 million. The Company has incurred operational losses and negative cash flows on a cumulative basis since inception. For the six months ended January 31, 2022, the Company incurred a net loss from operating activities of approximately \$0.8 million and cash outflows from operations of \$1.6 million, compared to a net income from operations of \$0.6 million and cash outflows from operations of \$0.1 million for the same period in fiscal 2021. The following table is a list of commitments the Company has:

For the three months ended October 31, 2021

	Total	Less than 1 year	1 to 3 years	4 to 5 years	After 5 years
	\$	\$	\$	\$	\$
Debt	6,161,322	6,121,322	40,000	-	-
Accounts payable and accrued liabilities	6,209,571	6,209,571	-	-	-
Advance from shareholder	500,000	500,000	-	-	-
Lease liabilities	2,238,558	147,919	516,897	409,550	1,164,192
Royalty provision	62,673	62,673	-	-	-
Total debt	15,172,124	13,041,485	556,897	409,550	1,164,192

Operating activities

MedMira incurred cash outflows from operations of approximately \$1.6 million for the six months ended January 31, 2022, compared to cash outflows of \$0.1 million for the same period in fiscal 2021.

Financing activities

Cash inflows from financing activities were \$2.6 million for the six months ended January 31, 2022, compared to cash outflows of \$0.2 million for the same period in fiscal 2021.

Debt

As at January 31, 2022, the Company had loans payable with a carrying value of \$6.2 million compared to \$9.2 million at July 31, 2021. The Company was in negotiations with all of its debt holders to ensure realistic debt repayment plans, which shall enable the Company to use its working capital for its growth and ensure its future stability. Subsequent to Q2 FY2022, The Province of Nova Scotia and the Company entered into a forbearance agreement which allows to defer principal and interest payments. As part of the agreement the Company provides regular updates on its progress and the milestone achieved. Due to its structure, which includes a review every six months, the Company must classify this as a current liability. The Province of Nova Scotia represents the largest debtholder with a carrying value of \$3.1 million out of the \$6.2 million loans payable. All other loans are currently in default due to non-payment of principal and interest and therefore show as a current liability on the balance sheet.

Further discussion on liquidity and capital resources can be found in this document in the Liquidity Risk section, Risk and Uncertainties section of this document and in Notes 2 and 8 of the Company's consolidated financial statements for the three months ended January 31, 2022.

Equity/Shares

The Company is authorized to issue an unlimited number of common shares without par value. During the six months ended January 31, 2022, the Company has issued 36,069,844 common shares. The number of issued and outstanding common shares on January 31, 2022 was 697,445,660. The Company is also authorized to issue an unlimited number of Series A preferred shares redeemable at \$0.01 per share after March 31, 2010, convertible into an equal number of common shares upon the Company meeting certain milestones. There were 5,000,000 Series A preferred shares issued and outstanding on January 31, 2022.

The Company had 13,711,496 outstanding stock warrants on January 31, 2022. The outstanding warrants have a weighted exercise price of ranging of \$0.15 per share and an expiry date of July 17, 2022. The number of outstanding common share options on January 31, 2022 was nil.

Off balance sheet arrangements

The Company was not party to any off balance sheet arrangements as of January 31, 2022.

Capital Management and Financial Risks

Liquidity risk

The accompanying consolidated financial statements have been prepared on the basis of IFRS applicable to a going-concern, which contemplates the realization of assets and liquidation of liabilities during the normal course of operations. However, certain adverse conditions and events cast significant doubt upon the validity of this assumption.

The Company has incurred losses and negative cash flows from operations on a cumulative basis since inception. For the six months ended January 31, 2022, the Company realized a net loss of \$1.0 million (January 31, 2021 – net income of \$0.3 million), consisting of a net loss from operations of \$0.8 million (January 31, 2021 – net income of \$0.6 million), and other non-operating losses of \$0.2 million (January 31, 2021 – \$0.3 million). Negative cash inflows from operations were \$1.6 million (January 31, 2021 – net outflows of \$0.1 million). As at January 31, 2022, the Company had an accumulated deficit of \$94.4 million (July 31, 2021 – \$93.5 million) and a negative working capital position of \$11.6 million (July 31, 2021 – \$15.8 million). In addition, as at January 31, 2022, \$6.1 million of debt was in default. The Company currently has insufficient cash to fund its operations for the next 12 months. In addition to its ongoing working capital requirements, the Company must secure sufficient funding for its research and development programs for existing commitments, including its current portion of debt of approximately \$6.1 million. These material uncertainties may cast significant doubt about the Company's ability to continue as a going concern.

The Company's objectives in managing capital are to ensure it can meet its ongoing working capital requirements. The Company must secure sufficient capital to support its capital requirements for research and development programs, existing commitments, including its current portion of debt of approximately \$6.1 million, as well as growth opportunities.

Management dedicates significant time to pursuing investment alternatives that will fund the Company's operations and growth opportunities so it can continue as a going concern. Debt arrangements were also ongoing with the Company's major shareholder and other debt holders. Subsequent to the close of the first quarter of fiscal year 2021, the Company, has generated additional revenues from product sales, product development and license fees, which support the Company's on-going operating costs and provide funding for its product development activities. Management continues to work closely with its main investor to support any additional cash requirements if needed, nevertheless there is no assurance that this initiative would be successful.

The Company is subject to risks associated with early stage companies, including but not limited to, dependence on key individuals, competition from substitute services and larger companies, and the requirement for the continued successful development and marketing of its products and services. The Company's ability to continue as a going-concern is dependent upon its ability to generate positive cash flow from operations and secure additional financing and the continued support of its lenders and shareholders. These financial statements do not reflect the adjustments to carrying values of assets and liabilities and the reported expenses and statement of financial position classifications that would be necessary were the going-concern assumption not appropriate. These adjustments could be material

Credit risk

The Company exposed to credit risk in relation to its trade accounts receivable. To mitigate such risk, the Company continuously monitors the financial condition of its customers and reviews the credit history or worthiness of each new customer. The Company mitigates this risk by requiring a 100% down payment for any orders received by new clients at the time of purchase. The Company establishes an allowance for doubtful accounts based on specific credit risk of its customers by examining such factors as the number of overdue days of the customers' balance outstanding as well as the customers' collection history. Since 87% of the Company's sales are with three large international companies with which the Company has distribution agreements since over 10 years, there is no significant concentration of credit risk.

Trade and other receivables include amounts that are past due as of January 31, 2022 for which the Company has not recognized an allowance for doubtful accounts because there has not been a significant change in the credit quality of the customer and the amounts are still considered recoverable.

Currency risk

MedMira receives most of its revenues in foreign currencies and incurs expenses in U.S. and Canadian currencies. As a result, the Company is subject to uncertainty as foreign exchange rates fluctuate. The exchange fluctuations from year to year have accounted for a significant portion of the Company's exchange gain and loss. Most sales are in USD, however, they are recorded at the exchange rate prevailing on or near the transaction date and collected in a timely manner.

The Company also experiences currency exposure resulting from balance sheet fluctuations of U.S and CHF denominated cash, U.S. and CHF accounts receivable, US and CHF denominated accounts payable and CHF denominated promissory notes.

MedMira mitigates this currency risk by maintaining a balance of USD currency which is used to pay down U.S.-denominated liabilities and replenishes the balance through U.S.-denominated revenues.

Interest rate risk

The Company is not exposed to interest rate risk as it borrows funds at fixed rates.

Related party transactions

The following transactions occurred with related parties during the three months ended January 31, 2022:

- Short term loans totalling \$5,000 were repaid to employees (July 31, 2021 - \$56,364)
- Short term loans totalling \$55,846 were received from an officer (July 31, 2021 - \$26,884)
- A short term loans totalling \$1,482,671 was received from MedMira Holding AG (July 31, 2021 - nil)
- Short term loans totalling \$234,631 were received from the largest shareholder of MedMira Holding AG (July 31, 2021 – nil).
- Short terms loans of \$157,865 owed to an officer were converted to common shares (July 31, 2021 – nil).
- Long term loans of \$201,002 owed to an officer were converted to common shares (July 31, 2021 – nil).
- Short term loans owed to Ritec AG were converted to common shares (July 31, 2021 – nil).
- Long term loans of \$756,305 owed to MedMira Holding AG were converted to common shares (July 31, 2021 – nil)
- Short term loans of \$335,615 owed to MedMira Holding AG were converted to common shares (July 31, 2021 - nil).
- Common shares were issued in the value of \$1,665,691 to MedMira Holding AG from the receipt of cash (July 31, 2021 – nil).
- A payment of \$67,328 (July 31, 2021 – nil) was made to Ritec AG as payment towards a royalty agreement.

The following balances with related parties were outstanding at January 31, 2022:

- Salaries and benefits totalling \$1,180,840 were due to officers (July 31, 2021 - \$1,142,165).
- A long term loan totalling \$5,264 was due to the Chief Financial Officer (July 31, 2021 - \$207,792).
- A royalty provision was owed to MedMira Holding AG of \$62,673 (July 31, 2021 - \$130,000).
- Short term loans totalling \$174,891 were owed to the Chief Financial Officer (July 31, 2021 - \$277,662).

Compensation summary

A) Officers for Q2 FY2022

Name and Principal Position	Paid Compensation (\$)	Accrued Compensation Current year (\$)	Share- and Option-based Awards* (\$)	All other compensation (\$)	Total Compensation current year (\$)	Paid Compensation related to previous fiscal years (\$)	Accrued Compensation related to previous fiscal years (\$)
Hermes Chan CEO	20,345	6,578	-	-	26,923	-	541,127
Markus Meile CFO	-	16,154	-	-	16,154	-	582,922

¹ All other compensation includes pension fund contributions and/or bonuses paid out.

*The Company makes certain estimates and assumptions when calculating the fair value of option-based awards. The Company uses an option-pricing model, which includes significant assumptions including estimates of the expected volatility, expected life, expected dividend rate and expected risk-free rate of return. Changes in these assumptions may result in a material change to the amounts recorded for the issuance of stock options.

B) Directors for Q2 FY2022

Name and Principal Position	Paid Compensation (\$)	Accrued Compensation Current year (\$)	Share- and Option-based Awards* (\$)	Total Compensation current year (\$)	Paid Compensation related to previous fiscal years (\$)	Accrued Compensation related to previous fiscal years (\$)
Hermes Chan, Director,	-	-	-	-	-	-
Steven Cummings, Director,	-	-	-	-	-	-
Jianhe Mao, Director,	-	-	-	-	-	-
Thomas Bergmann, Director,	-	-	-	-	-	-

*The Company makes certain estimates and assumptions when calculating the fair value of option-based awards. The Company uses an option pricing model which includes significant assumptions including estimates of the expected volatility, expected life, expected dividend rate and expected risk-free rate of return. Changes in these assumptions may result in a material change to the amount recorded for the issuance of stock options.

Internal control systems and disclosure controls

To ensure the integrity and objectivity of the data, management maintains a system of internal controls comprising of written policies, procedures and a program of internal reviews which provides reasonable assurance that transactions are recorded and executed in accordance with its authorization that assets are properly safeguarded and that reliable financial records are maintained.

Management is currently updating existing standardized processes to improve internal controls and reduce compliance costs. The updated controls will help improve timeliness and accuracy of financial records as well as continue to ensure that the Company's assets are properly safeguarded.

Disclosure controls and procedures within MedMira have been designed to provide reasonable assurance that all relevant information is identified to the Disclosure Committee to ensure appropriate and timely decisions are made regarding public disclosure.

Management, under the supervision of the Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's internal control over financial reporting and based on this evaluation, has concluded that internal control over financial reporting was effective as at January 31, 2022.

Due to inherent limitations, internal control over financial reporting and disclosure controls can provide only reasonable assurances and may not prevent or detect misstatements. Furthermore, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Audit Committee of the Board of Directors of MedMira reviewed this MD&A, and the condensed interim consolidated financial statements of MedMira for January 31, 2022 and MedMira's Board of Directors approved these documents prior to release.

Risk and uncertainties

The Company's base of activity has expanded to manufacturing products for distribution in international markets, making it difficult to accurately predict future operating results. Actual future results may differ significantly in any forward-looking statements. Currently, the Company is not making sufficient sales to be self-sustaining. As a result, the Company's financial condition, business and operations, and intellectual property are exposed to a variety of risk factors. These risks include, but are not limited to, the following:

Risks and uncertainties related to the Company's financial condition

Need for additional capital

Cash generated from operations is insufficient to satisfy working capital and capital expenditure requirements, and the Company is operating with a substantial working capital deficit. The Company will need to secure additional financing in the near term in order to continue as a going concern which may include the sale of additional equity or debt securities or obtaining additional credit facilities. In recent quarters, the Company has relied on temporary funding advanced from key investors. There can be no assurance that this source of funding will continue to be available on acceptable terms, and additional capital may not be available on satisfactory terms, or at all. Management is pursuing other financing alternatives to fund the Company's operations so it can continue as a going-concern.

The Company intends to continue to explore opportunities to enter into supply agreements, joint venture relationships, and other special purpose vehicles with third parties from time to time in order to continue to commercialize its patent

pending technology and other intellectual property. Such arrangements may include the issuance of equity or debt securities of the Company, subject to compliance with the applicable requirements of the Canadian securities regulatory authorities and the TSX-V.

Any additional equity financing may result in the dilution of shareholders, and debt financing, if available, may include restrictive covenants. MedMira's future liquidity and capital funding requirements will depend on numerous factors including:

- the extent to which new products and products under development are successfully developed, gain market acceptance and become and remain competitive;
- the costs and timing of further expansion of sales, marketing and manufacturing activities and facility's needs;
- the timing and results of clinical studies and regulatory actions regarding potential products; and
- the costs and timing associated with business development activities, including potential licensing of technologies patented by others.

Continued operations will be contingent on generating sufficient revenues or raising additional capital or debt financing. There is no assurance that these initiatives will be successful.

Fluctuations in revenue

The Company's quarterly and annual revenues may fluctuate due to several factors, including seasonal variations in demand, competitive pressure on average selling prices, customer order patterns, the rate of acceptance of the Company's products, product delays or production inefficiencies, regulatory uncertainties or delays, costs and timing associated with business development activities, including potential licensing of technologies, international market conditions and variations in the timing and volume of distributor purchases. The healthcare industry traditionally is not impacted by seasonal demand. The impact of one or a combination of several of these factors could have a significant adverse effect on the operations of the Company. In addition, changes in existing collaborative relationships, as well as the establishment of new relationships, product licensing and other financing relationships, could materially impact the Company's financial position and results from operations.

Effects of inflation and foreign currency fluctuations

A significant portion of the Company's revenue and expenses are in U.S. dollars, and therefore subject to fluctuations in exchange rates. There is a risk that significant fluctuations in exchange rates may impact the Company's ability to sell its products and, thereby, have a material adverse impact on the Company's results of operations.

Possible volatility of share price

The stock market has from time to time experienced significant price and volume fluctuations that may be unrelated to the operating performance of the Company. In addition, the market price of the Company's common shares, like the share prices of many publicly traded biotechnology companies, has been highly volatile. Announcement of technology innovations or new commercial products by the Company or its competitors, developments or disputes concerning patent or proprietary rights, publicity regarding actual or potential medical results relating to products under development by the Company or its competitors, regulatory developments in both the U.S. and foreign countries, public concern as to the safety of biotechnology products and economic and other external factors, as well as period to period fluctuations in financial results may have a significant impact on the market price of the Company's common shares. It is likely that in some future quarter the Company's operating results will be below the expectations of the public market analysts and investors. In such event, the price of the Company's common shares would likely be materially adversely affected.

Risks and uncertainties related to the Company's business and operations

Lack of market acceptance

MedMira's ability to market its diagnostic products will, in part, depend on its or its partners' ability to convince users that these products represent viable and efficacious diagnostic tests. There can be no assurance that MedMira will be successful in this regard.

Competition

The *in vitro* diagnostics market in which the Company participates is highly complex and competitive. It is comprised of both large healthcare companies that have substantially greater financial, scientific, and other resources than MedMira and a variety of international companies producing diagnostic products of varying quality. In the developed regions of the world with strong healthcare infrastructures, the *in vitro* diagnostics market for serious and emerging infectious diseases such as HIV and Hepatitis C has been focused on diagnostic tests using instrument based platforms designed for clinical laboratories. Diagnostic products designed for use in non-laboratory settings at the point-of-care or for use in laboratories or public health clinics using non-instrument based platforms for the screening and diagnosis of infectious diseases are becoming more mainstream in both the developed and developing regions of the world. Competition in this sector of the market is intense and is expected to increase. Many of the companies have substantially greater resources available for development, marketing and distribution of these products than does MedMira.

Significant development effort required

Products currently under development by MedMira require additional development, testing and investment prior to any final commercialization. There can be no assurance that these products or any future products will be successfully developed, prove to be safe and effective in clinical trials, receive applicable regulatory approvals, be capable of being produced in commercial quantities at reasonable costs or be successfully marketed. The long term success of MedMira must be considered in light of the expenses, difficulties and delays frequently encountered in connection with the development of new technology and the competitive and highly regulated environment in which MedMira operates.

Uncertainties in sales cycles in target markets

MedMira markets and distributes its products to both developed and developing regions of the world. Sales cycles in developed regions of the world are somewhat conventional, however, timing of registrations and other activities surrounding the sale of product into a specific market are unpredictable and highly dependent on third party and government organizations to complete certain processes before a sales transaction can take place. In developing regions of the world where MedMira and its strategic partners are working to close deals, the sales cycle timing is highly uncertain given a number of factors including political and economic turmoil, as well as bureaucratic processes necessary to do business in these regions.

High degree of regulation

MedMira operates in a highly regulated industry and is subject to the authority and approvals of certain regulatory agencies, including Health Canada, the FDA, the CFDA, CE Mark and applicable health authorities in other countries, with regard to the development, testing, manufacture, marketing and sale of its products. The process of obtaining such approvals can be costly and time consuming, and there can be no assurance that regulatory approvals will be obtained or maintained. Any failure to obtain (or significant delay in obtaining) or maintain Health Canada, FDA, Notified Body or CFDA approvals (or, to a lesser extent, approval of applicable health authorities in other countries) for MedMira's new or existing products could materially adversely affect MedMira's ability to market its products successfully and could therefore have a material adverse effect on the business of MedMira.

Ability to retain and attract key management and other experienced personnel

Since its inception, the Company has been, and continues to be, dependent in its ability to attract and maintain key scientific and commercial personnel upon whom the Company relies for its product innovations and commercialization programs. Loss of key personnel individually or as a group could have significant adverse impact on the Company's immediate and future achievement of operating results.

Limited sales and marketing resources and reliance on key distributors to market and sell the Company's product

Any revenues received by the Company will be dependent on the efforts of third parties and there can be no assurance that such efforts will be successful. Failure to establish sustainable and successful sales and marketing programs with effective distributor support programs may have a material adverse effect on the Company.

Commercialization of the Company's products is expensive and time consuming. In the United States, a relationship has been established with a number of distributors to support the logistics and distribution of the Company's products. The Company will rely on the joint efforts of Medline Industries and distributors Cardinal Health, a Fortune 100 company, and VWR International to distribute MedMira's product line.

Outside the United States, the Company pursues collaborative arrangements with established pharmaceutical and distribution companies for marketing, distribution, and sale of its products.

In China, MedMira has formed a strategic partnership with Triplex to market and distribute the Company's rapid HIV test within the assigned territory. This strategic partnership also encompasses the assembly and packaging of final product components.

If any of the Company's distribution agreements are terminated and the Company is unable to enter into alternative agreements, or if the Company elects to distribute new products directly, additional investment in sales and marketing resources would be required which would increase future selling, general and administrative expenses. The Company has limited experience in direct sales, marketing and distribution of its products. A failure of the Company to successfully market its products would have a material and adverse effect on the Company.

Manufacturing capabilities and scale-up

The Company must manufacture its products in compliance with regulatory requirements, in sufficient quantities and on a timely basis, while maintaining product quality and acceptable manufacturing costs. If it is unable to manufacture or contract for such capabilities on acceptable terms for its products under development, MedMira's plans for commercialization could be materially adversely affected.

MedMira's manufacturing facilities are, or will be, subject to periodic regulatory inspections by the FDA, CE, CFDA and other regulatory agencies and these facilities are subject to Quality System Regulations requirements of the FDA and other standards organizations. MedMira may not satisfy such regulatory or standards requirements, and any failure to do so would have a material adverse effect on the Company.

In addition, production and scale-up of manufacturing for new products may require the development and implementation of new manufacturing technologies and expertise. Manufacturing and quality control problems may arise as the Company attempts to scale-up manufacturing and such scale-up may not be achieved in a timely manner or at commercially reasonable cost, or at all.

Rapidly changing technology

The *in vitro* diagnostic testing field as a whole is characterized by rapidly advancing technology that could render MedMira's products obsolete at any time and thereby adversely affect the financial condition and future prospects of the Company.

Uncertainties regarding healthcare reimbursement and reform

The future revenues and profitability of diagnostic companies as well as the availability of capital may be affected by the continuing efforts of government and third party payers to contain or reduce costs of healthcare through various means. For example, in certain foreign markets, pricing or profitability is subject to government control. In the US, there has been, and the Company expects that there will continue to be, a number of federal and state proposals to implement similar government controls. While the Company cannot predict whether any such legislative or regulatory proposals will be adopted, the announcement or adoption of such proposals could have a material adverse effect on the Company's results of operations.

Product liability

MedMira may be subject to claims of personal injury and could become liable to clinical laboratories, hospitals and patients for injuries resulting from the use of its products. MedMira could suffer financial loss due to defects in its products and such financial loss together with litigation expenses could have a material adverse effect on its operations. MedMira has obtained product liability insurance to protect against possible losses of this nature. However, no assurance can be given that such insurance will be adequate to cover all claims or that MedMira will be able to maintain such insurance at a reasonable cost.

COVID-19 related uncertainties

Since January 31, 2021, the outbreak of COVID-19 (coronavirus) has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures have caused material disruption to businesses globally resulting in an economic slowdown, and global equity markets have experienced significant volatility. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the outcome of government and central bank interventions. The Company has not recorded any major negative impact at this time by the global pandemic except higher logistic costs and longer lead times during 2020 which have stabilised in 2021. Furthermore, the Company managed to stay operational and continued its development and manufacturing activities throughout the various lock downs. In addition, the Company was able to increase its work force and with the stringent safety measures put in place, recorded no COVID-19 related cases. Despite this, the management and the board of directors of MedMira Inc. caution the market with regard to the future and any potential negative impact the continuous spread of COVID-19 may have at the operational stability of the Company. In management's estimation, these events have not had a material unrecorded impact on the carrying value of assets and liabilities reported in these financial statements as at July 31, 2021. The duration and impact of the COVID-19 pandemic remains unclear at this time. Therefore, it is not possible to reliably estimate the duration and severity of these consequences, as well as their impact on the financial position and results of the company for future periods.

Risks and uncertainties related to the Company's intellectual property

No assurance of patent protection

MedMira has filed patent applications in the United States, Canada, China, and other foreign countries relating to various aspects of its rapid diagnostic platform, processes, reagents, and equipment. Although it is management's belief that the patents for which the Company applied may be issued, there can be no such assurance, nor can MedMira assure that competitors will not develop functionally similar or superior diagnostic testing devices. Moreover, there is a question as to the extent to which biotechnology discoveries and related products and processes can effectively be protected by patents. The law regarding the breadth or scope of biotechnology patents is new and evolving. No assurance can be given that, if a patent issued to MedMira is challenged, it will be held valid and enforceable or will be found to have a scope sufficiently broad to cover competitors' products or processes. The cost of enforcing MedMira's patent right, if any, in lawsuits that it may bring against infringers may be significant and could limit MedMira's operations.

Possible patent infringement

The extent to which biotechnology discoveries and related products and processes can be effectively protected by patents and be enforceable is uncertain and subject to interpretation by the courts. The technologies, products, and processes of MedMira may be subject to claims of infringement on the patents of others and, if such claims are successful, could result in the requirement to access such technology by license agreement. There can be no assurance that such licenses would be available on commercially acceptable terms. If MedMira is required to acquire rights to valid and enforceable patents but cannot do so at reasonable cost, MedMira's ability to manufacture or market its products would be materially adversely affected. The cost of MedMira's defence against infringement charges by other patent holders may be significant and could limit MedMira's operations.